Securities
Nov. 27, 2010
Weak Biotech IPOs Continue
The initial public offering by Anacor Pharmaceuticals Inc. on Wednesday continued a downward trend for biotechnology IPOs.
Daily Journal Staff Writer
Anacor Pharmaceuticals Inc.'s initial public offering Wednesday marked a continued downward trend for biotechnology IPOs.
Palo Alto-based Anacor raised $60 million through the sale of 12 million shares priced at $5, but the company had said in a Nov. 2 Securities and Exchange Commission filing that it planned to raise as much as $97.3 million by selling up to 5.4 million shares at $16 to $18.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In